Loading
A phase 2 trial of DAT-2645 run by Danatlas Pharmaceuticals Co., Ltd, not yet recruiting.
A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer is a phase 2 interventional study registered as NCT07652073 by Danatlas Pharmaceuticals Co., Ltd, with 30 participants planned, started 2026-06-15. Conditions recorded: Advanced or Metastatic Ovarian Cancer. Interventions recorded: DAT-2645 tablet.
Shares DAT-2645, Danatlas Pharmaceuticals and the tag pipeline.
Shares Danatlas Pharmaceuticals and the tag pipeline.
Shares Danatlas Pharmaceuticals and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/